About the endTB project


endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels

Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners Unitaid and the Transformational Investment Capacity (TIC) of MSF. 

You can contact us, or follow us on Twitter.

Watch the two-minute animation

Groundbreaking endTB clinical trial results published in the New England Journal of Medicine

NEJM publication

On 29 January 2025, the New England Journal of Medicine (NEJM) published the manuscript of the endTB clinical trial results. [...] The publication in the NEJM, a leading peer-reviewed medical journal that publishes cutting-edge research advancing global healthcare, reinforces the strong scientific value of the evidence produced by endTB.

Read Lorenzo Guglielmetti's interview 

Requests to access the endTB data are now open (eDSI)

eDSI image

After 3 years of preparation, the endTB data is now open for requests! The endTB Data Sharing Initiative (eDSI) aims to give ethical, equitable and transparent access to endTB data for a range of users who share the common goal of increasing information to improve care for MDR-TB patients. It will include data from the endTB Observational study, the endTB and endTB-Q clinical trials. Researchers, research institutions, PhD students, and other relevant users are invited to analyze a ready set of data on MDR-TB to benefit people with MDR-TB! 

More information here

PIH MSF MSF Unitaid: Save Lives Faster Médecins Sans Frontières (MSF) Transformational Investment Capacity (TIC) logo